SAN FRANCISCO, Oct. 18, 2017 /PRNewswire/ -- Trianni, Inc.
("TRIANNI") today announced that Juno Therapeutics (NASDAQ: JUNO)
has entered into a license agreement for The Trianni Mouse™, a
best-in-class monoclonal antibody discovery platform. Juno intends
to use The Trianni Mouse with its proprietary high throughput,
single cell sequencing technology and direct-to-CAR screening to
rapidly identify fully-human binders for conversion to chimeric
antigen receptors in its engineered T cell programs.
"TRIANNI is pleased to bolster Juno's lead generation
capabilities through a license to The Trianni Mouse," stated Dr.
David Meininger, TRIANNI's Chief
Business Officer. "We are confident that Juno's deep expertise in
developing engineered T cells will potently synergize with the
industry-leading human antibody repertoires provided by The Trianni
Mouse."
"The Trianni Mouse offers an in vivo platform for
generating a diverse human antibody response to tumor targets of
interest," said Hy Levitsky, M.D., Juno's Chief Scientific
Officer.
"We look forward to using the technology to advance our
discovery efforts and build more effective, next-generation CAR T
cells."
No financial details were disclosed.
About Trianni, Inc.
Trianni, Inc. is a privately held
biotech company specializing in antibody discovery technology.
TRIANNI's lead technology, The Trianni Mouse™, is a powerful,
next-generation platform enabling efficient generation of fully-
human monoclonal antibodies. TRIANNI's transgenic platform
leverages a novel approach to design made possible by advances in
DNA synthesis and genomic modification technology making it a
best-in-class therapeutic antibody discovery platform. The
company is headquartered in San
Francisco, CA. Additional information about TRIANNI is
available through its corporate website, www.trianni.com.
Forward-Looking Statement
This
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934, including statements regarding
Juno's mission, progress, and business plans, and the potential of
The Trianni Mouse to advance Juno's discovery efforts and build
more effective, next-generation CAR T cells. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from such forward-looking
statements, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to, risks associated with: the
success, cost, and timing of Juno's product development activities
and clinical trials; Juno's ability to obtain regulatory approval
for and to commercialize its product candidates; Juno's ability to
establish a commercially-viable manufacturing process and
manufacturing infrastructure; regulatory requirements and
regulatory developments; success of Juno's competitors with respect
to competing treatments and technologies; Juno's dependence on
third-party collaborators and other contractors in Juno's research
and development activities, including for the conduct of clinical
trials and the manufacture of Juno's product candidates; Juno's
ability to attract and retain key scientific, quality
control/assurance, manufacturing or management personnel; Juno's
dependence on Celgene for the development and commercialization
outside of North America and
China of Juno's CD19 product
candidates and any other product candidates for which Celgene
exercises an option; Juno's dependence on JW Therapeutics
(Shanghai) Co., Ltd, over which
Juno does not exercise complete control, for the development and
commercialization of product candidates in China; Juno's ability to obtain, maintain, or
protect intellectual property rights related to its product
candidates; amongst others. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to Juno's business in general, see the information
Juno has included it its periodic reports and other documents filed
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Juno disclaims any
obligation to update these forward-looking statements.
Contact– Trianni, Inc.
David
Meininger
Chief Business Officer
1.866.674.9314
david.meininger@trianni.com
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
mandy.boyd@trianni.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/trianni-and-juno-therapeutics-sign-licensing-agreement-for-use-of-trianni-transgenic-mouse-platform-300538676.html
SOURCE Trianni, Inc.